Avid Bioservices Inc (CDMO)

[semper]

This is from 2011 but very interesting

Peregrine: Pre-Clinical Data Shows Synergic Effect of Bavituximab & Nexavar in Reducing Liver Cancer Tumor Growth; Phase I/II Trial Ongoing

At the American Association for Cancer Research (AACR), Peregrine showed that the combination of Bavituximab (2aG4) combined with Bayer’s sorafenib (Nexavar) can inhibit liver cancer tumor growth in mice by 95%, as compared with 80% for sorafenib alone (p<0.05). This combination is currently in Phase I/II human clinical trials.

The mean tumor weight of the group receiving Bavituximab in combination with sorafenib was 69% less than that of the group receiving sorafenib alone (127 mg versus 409 mg, n=10, p<0.01) after 59 days of treatment. Immunofluorescence analysis showed that treatment with Bavituximab in combination with sorafenib decreased blood vessel density from 14.2% to 4.5% (p<0.01), versus 10.3% (p<0.05) for our antibody or 8.4% (p<0.01) for sorafenib alone. Sorafenib more than doubles the amount of PS exposed on the blood vessels of HCC tumors.
Source:

Life Tech Capital/Dunn, April 5, 2011
Oncology Indication: Liver
Keyword: Clinical Trials/Pipeline
http://oncology.healthace.com/040511/Oncology_Report_040511_S6.pdf